FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody which specifically binds to nectin-2, or to a fragment of said antibody, as well as to a composition, a conjugate and a chimeric antigen receptor (CAR) containing same. Also disclosed is a nucleic acid coding a sequence of a heavy chain region and a light chain of said antibody or antibody fragment, as well as a cell and a cell population containing same.
EFFECT: invention is effective for treating tumours in which nectin-2 is overexpressed, as well as for diagnosing cancer in a subject on levels of nectin-2 expression.
22 cl, 12 dwg, 1 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
